Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain

Seiichi Yamano, Chi T. Viet, Dongmin Dang, Jisen Dai, Shigeru Hanatani, Tadahiro Takayama, Hironori Kasai, Kentaro Imamura, Ron Campbell, Yi Ye, John C. Dolan, William Myung Kwon, Stefan D. Schneider, Brian L. Schmidt

Research output: Contribution to journalArticle

Abstract

Virus-mediated gene delivery shows promise for the treatment of chronic pain. However, viral vectors have cytotoxicity. To avoid toxicities and limitations of virus-mediated gene delivery, we developed a novel nonviral hybrid vector: HIV-1 Tat peptide sequence modified with histidine and cysteine residues combined with a cationic lipid. The vector has high transfection efficiency with little cytotoxicity in cancer cell lines including HSC-3 (human tongue squamous cell carcinoma) and exhibits differential expression in HSC-3 (∼45-fold) relative to HGF-1 (human gingival fibroblasts) cells. We used the nonviral vector to transfect cancer with OPRM1, the-opioid receptor gene, as a novel method for treating cancer-induced pain. After HSC-3 cells were transfected with OPRM1, a cancer mouse model was created by inoculating the transfected HSC-3 cells into the hind paw or tongue of athymic mice to determine the analgesic potential of OPRM1 transfection. Mice with HSC-3 tumors expressing OPRM1 demonstrated significant antinociception compared with control mice. The effect was reversible with local naloxone administration. We quantified β-endorphin secretion from HSC-3 cells and showed that HSC-3 cells transfected with OPRM1 secreted significantly more β-endorphin than control HSC-3 cells. These findings indicate that nonviral delivery of the OPRM1 gene targeted to the cancer microenvironment has an analgesic effect in a preclinical cancer model, and nonviral gene delivery is a potential treatment for cancer pain.

Original languageEnglish (US)
Pages (from-to)240-251
Number of pages12
JournalPain
Volume158
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

mu Opioid Receptor
Pain
Genes
Neoplasms
beta-Endorphin
Tongue
Transfection
Analgesics
Viruses
Tumor Microenvironment
Opioid Receptors
Naloxone
Histidine
Nude Mice
Chronic Pain
Cysteine
HIV-1
Squamous Cell Carcinoma
Fibroblasts
Lipids

Keywords

  • Cancer pain
  • Gene delivery
  • OPRM1
  • Oral squamous cell carcinoma
  • μ-opioid receptor

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain. / Yamano, Seiichi; Viet, Chi T.; Dang, Dongmin; Dai, Jisen; Hanatani, Shigeru; Takayama, Tadahiro; Kasai, Hironori; Imamura, Kentaro; Campbell, Ron; Ye, Yi; Dolan, John C.; Kwon, William Myung; Schneider, Stefan D.; Schmidt, Brian L.

In: Pain, Vol. 158, No. 2, 01.02.2017, p. 240-251.

Research output: Contribution to journalArticle

Yamano, S, Viet, CT, Dang, D, Dai, J, Hanatani, S, Takayama, T, Kasai, H, Imamura, K, Campbell, R, Ye, Y, Dolan, JC, Kwon, WM, Schneider, SD & Schmidt, BL 2017, 'Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain' Pain, vol 158, no. 2, pp. 240-251. DOI: 10.1097/j.pain.0000000000000750
Yamano S, Viet CT, Dang D, Dai J, Hanatani S, Takayama T et al. Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain. Pain. 2017 Feb 1;158(2):240-251. Available from, DOI: 10.1097/j.pain.0000000000000750

Yamano, Seiichi; Viet, Chi T.; Dang, Dongmin; Dai, Jisen; Hanatani, Shigeru; Takayama, Tadahiro; Kasai, Hironori; Imamura, Kentaro; Campbell, Ron; Ye, Yi; Dolan, John C.; Kwon, William Myung; Schneider, Stefan D.; Schmidt, Brian L. / Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain.

In: Pain, Vol. 158, No. 2, 01.02.2017, p. 240-251.

Research output: Contribution to journalArticle

@article{e43be15f7ac6466195c0bcaf623699fe,
title = "Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain",
abstract = "Virus-mediated gene delivery shows promise for the treatment of chronic pain. However, viral vectors have cytotoxicity. To avoid toxicities and limitations of virus-mediated gene delivery, we developed a novel nonviral hybrid vector: HIV-1 Tat peptide sequence modified with histidine and cysteine residues combined with a cationic lipid. The vector has high transfection efficiency with little cytotoxicity in cancer cell lines including HSC-3 (human tongue squamous cell carcinoma) and exhibits differential expression in HSC-3 (∼45-fold) relative to HGF-1 (human gingival fibroblasts) cells. We used the nonviral vector to transfect cancer with OPRM1, the-opioid receptor gene, as a novel method for treating cancer-induced pain. After HSC-3 cells were transfected with OPRM1, a cancer mouse model was created by inoculating the transfected HSC-3 cells into the hind paw or tongue of athymic mice to determine the analgesic potential of OPRM1 transfection. Mice with HSC-3 tumors expressing OPRM1 demonstrated significant antinociception compared with control mice. The effect was reversible with local naloxone administration. We quantified β-endorphin secretion from HSC-3 cells and showed that HSC-3 cells transfected with OPRM1 secreted significantly more β-endorphin than control HSC-3 cells. These findings indicate that nonviral delivery of the OPRM1 gene targeted to the cancer microenvironment has an analgesic effect in a preclinical cancer model, and nonviral gene delivery is a potential treatment for cancer pain.",
keywords = "Cancer pain, Gene delivery, OPRM1, Oral squamous cell carcinoma, μ-opioid receptor",
author = "Seiichi Yamano and Viet, {Chi T.} and Dongmin Dang and Jisen Dai and Shigeru Hanatani and Tadahiro Takayama and Hironori Kasai and Kentaro Imamura and Ron Campbell and Yi Ye and Dolan, {John C.} and Kwon, {William Myung} and Schneider, {Stefan D.} and Schmidt, {Brian L.}",
year = "2017",
month = "2",
doi = "10.1097/j.pain.0000000000000750",
volume = "158",
pages = "240--251",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Ex vivo nonviral gene delivery of μ-opioid receptor to attenuate cancer-induced pain

AU - Yamano,Seiichi

AU - Viet,Chi T.

AU - Dang,Dongmin

AU - Dai,Jisen

AU - Hanatani,Shigeru

AU - Takayama,Tadahiro

AU - Kasai,Hironori

AU - Imamura,Kentaro

AU - Campbell,Ron

AU - Ye,Yi

AU - Dolan,John C.

AU - Kwon,William Myung

AU - Schneider,Stefan D.

AU - Schmidt,Brian L.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Virus-mediated gene delivery shows promise for the treatment of chronic pain. However, viral vectors have cytotoxicity. To avoid toxicities and limitations of virus-mediated gene delivery, we developed a novel nonviral hybrid vector: HIV-1 Tat peptide sequence modified with histidine and cysteine residues combined with a cationic lipid. The vector has high transfection efficiency with little cytotoxicity in cancer cell lines including HSC-3 (human tongue squamous cell carcinoma) and exhibits differential expression in HSC-3 (∼45-fold) relative to HGF-1 (human gingival fibroblasts) cells. We used the nonviral vector to transfect cancer with OPRM1, the-opioid receptor gene, as a novel method for treating cancer-induced pain. After HSC-3 cells were transfected with OPRM1, a cancer mouse model was created by inoculating the transfected HSC-3 cells into the hind paw or tongue of athymic mice to determine the analgesic potential of OPRM1 transfection. Mice with HSC-3 tumors expressing OPRM1 demonstrated significant antinociception compared with control mice. The effect was reversible with local naloxone administration. We quantified β-endorphin secretion from HSC-3 cells and showed that HSC-3 cells transfected with OPRM1 secreted significantly more β-endorphin than control HSC-3 cells. These findings indicate that nonviral delivery of the OPRM1 gene targeted to the cancer microenvironment has an analgesic effect in a preclinical cancer model, and nonviral gene delivery is a potential treatment for cancer pain.

AB - Virus-mediated gene delivery shows promise for the treatment of chronic pain. However, viral vectors have cytotoxicity. To avoid toxicities and limitations of virus-mediated gene delivery, we developed a novel nonviral hybrid vector: HIV-1 Tat peptide sequence modified with histidine and cysteine residues combined with a cationic lipid. The vector has high transfection efficiency with little cytotoxicity in cancer cell lines including HSC-3 (human tongue squamous cell carcinoma) and exhibits differential expression in HSC-3 (∼45-fold) relative to HGF-1 (human gingival fibroblasts) cells. We used the nonviral vector to transfect cancer with OPRM1, the-opioid receptor gene, as a novel method for treating cancer-induced pain. After HSC-3 cells were transfected with OPRM1, a cancer mouse model was created by inoculating the transfected HSC-3 cells into the hind paw or tongue of athymic mice to determine the analgesic potential of OPRM1 transfection. Mice with HSC-3 tumors expressing OPRM1 demonstrated significant antinociception compared with control mice. The effect was reversible with local naloxone administration. We quantified β-endorphin secretion from HSC-3 cells and showed that HSC-3 cells transfected with OPRM1 secreted significantly more β-endorphin than control HSC-3 cells. These findings indicate that nonviral delivery of the OPRM1 gene targeted to the cancer microenvironment has an analgesic effect in a preclinical cancer model, and nonviral gene delivery is a potential treatment for cancer pain.

KW - Cancer pain

KW - Gene delivery

KW - OPRM1

KW - Oral squamous cell carcinoma

KW - μ-opioid receptor

UR - http://www.scopus.com/inward/record.url?scp=85018634689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018634689&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000000750

DO - 10.1097/j.pain.0000000000000750

M3 - Article

VL - 158

SP - 240

EP - 251

JO - Pain

T2 - Pain

JF - Pain

SN - 0304-3959

IS - 2

ER -